Abcam: Appointment of Vice President of Investor Relations

Abcam plc

PR96710

 

CAMBRIDGE, England, June 27, 2022 /PRNewswire=KYODO JBN/ --

 

Abcam [https://corporate.abcam.com/] plc ("Abcam," "Company," "Group") (AIM:

ABC) (Nasdaq: ABCM), a global leader in the supply of life science research

tools, today announces the appointment of Tommy Thomas as Vice President of

Investor Relations.

 

Tommy, who will be based in our Waltham, MA office, has over 20 years'

experience in the life sciences sector, largely focused in the area of research

tools. He joins Abcam from Avantor, where he was Vice President, Investor

Relations for several years. Prior to this he was Vice President of Investor

Relations, and then Chief Financial Officer of Global Services at Perkin Elmer.

Before joining Perkin Elmer, Tommy spent eight years as a buy side analyst for

TIAA-CREF focused on the medical technology & life science tools areas.

 

Michael Baldock, Chief Financial Officer of Abcam, said: "I am delighted to

have Tommy joining us. His deep industry experience, significant investor

relations expertise, and strong institutional investor and research analyst

relationships are a major step forward for us. Tommy will be a real asset to

Abcam and our investors as we continue to grow, differentiate ourselves in the

marketplace, and deliver value for all our stakeholders."

 

Tommy Thomas commented: "I am very pleased to join Abcam at this important time

in its evolution. The Company's customer-centric model focusing on new product

innovation for researchers and clinicians in the life sciences industry is

highly differentiated. I look forward to learning and telling our story as I

build new friendships along the way."

 

About Abcam plc

 

As an innovator in reagents and tools, Abcam's purpose is to serve life science

researchers globally to achieve their mission, faster. Providing the research

and clinical communities with tools and scientific support, the Company offers

highly validated antibodies, assays and other research tools to address

important targets in critical biological pathways.

 

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's

ambition is to be the most influential company in life sciences by helping

advance global understanding of biology and causes of disease, which, in turn,

will drive new treatments and improved health.

 

Abcam's worldwide customer base of approximately 750,000 life science

researchers uses Abcam's antibodies, reagents, biomarkers and assays. By

actively listening to and collaborating with these researchers, the Company

continuously advances its portfolio to address their needs. A transparent

programme of customer reviews and datasheets, combined with an industry-leading

validation initiative, gives researchers increased confidence in their results.

 

Founded in 1998 and headquartered in Cambridge, UK, the Company has served

customers in more than 130 countries. Abcam's ordinary shares are listed on the

London Stock Exchange (AIM: ABC) and its American Depositary Shares (ADSs)

trade on the Nasdaq Global Market (Nasdaq: ABCM).

 

Please visit https://corporate.abcam.com to find out more.

 

Logo - https://mma.prnewswire.com/media/1670705/Abcam_Logo.jpg

 

Source: Abcam plc

 

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中